Guinea Begins Ebola ‘Ring Vaccination’ Trial; Chinese Researchers Report Results From Another Vaccine Trial

CIDRAP News: Ebola vaccine trial launches in Guinea; Chinese vaccine test detailed
“In an effort to see if a vaccine might be used to drown out Ebola flare-ups, a new trial launched in an area of Guinea where cases have occurred recently, while Chinese researchers reported the first human trial results for a different type of vector vaccine. … [T]he Chinese study has been quickly adapted, with several research questions still to be settled before it proceeds to the next testing phase…” (Schnirring, 3/25).

International Business Times: Ebola crisis: First tests as ring vaccination starts in Guinea
“The Guinean government has on Wednesday (25 March) initiated the very first efficacy trial of an Ebola vaccine this week in Basse-Guinée, one of the country’s virus hotspots. Along with the World Health Organization (WHO), the authorities are rolling out ring vaccination tests of VSV-EBOV, an Ebola vaccine developed by the Public Health Agency of Canada…” (Buchanan, 3/25).

TIME: Ebola Vaccine Trial Starts in Guinea
“…The trial is using what’s called a ‘ring vaccination’ strategy, which means that when a person is infected with Ebola, a group, or ring, of their contacts will be vaccinated. Some of the contacts will be vaccinated immediately, and some will be vaccinated three weeks later…” (Sifferlin, 3/25).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.